CP
ECYT

Corbenic Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Corbenic Partners’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-32,639
Closed -$83K – 227
2016
Q4 		$83K Hold
32,639
– – 0.09% 51
2016
Q3 		$101K Hold
32,639
– – 0.11% 49
2016
Q2 		$105K Buy
32,639
+2,000
+7% +$7.33K 0.11% 45
2016
Q1 		$95K Buy
30,639
+3,500
+13% +$11.4K 0.1% 43
2015
Q4 		$109K Buy
+27,139
New +$125K 0.1% 41

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Corbenic Partners's ECYT Position: Q1 2017 in Review

Corbenic Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 32,639 shares — an estimated $83K sold.

Corbenic Partners first reported a position in ECYT in Q4 2015 and held it in 5 quarters. The position peaked at $109K in Q4 2015. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

  • Corbenic Partners reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Corbenic Partners sold 32,639 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $83K.
  • Corbenic Partners first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 5 quarters.
  • Corbenic Partners's Endocyte, Inc. Common Stock position peaked at $109K in Q4 2015.
  • 82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Corbenic Partners's 13F filing for Q1 2017, filed 26 Apr 2017.